Obtain a Sample

Apply Sample

Load Sample Plate

Fire Laser

Data Analysis

Results

qode-eliptic-slider

The Our Process

OBTAIN SAMPLE

Obtain an appropriate sample for the selected test. A simple pinprick of blood, urine, serum sample or non-invasively collected embryo culture fluid sample.

qode-eliptic-slider

The Our Process

APPLY SAMPLE

The sample is applied on stainless steel or single-use plastic MALDI target plate. It is mixed with a matrix, a substance that can absorb the laser energy and create ions from the sample molecules.

qode-eliptic-slider

The Our Process

LOAD SAMPLE PLATE

The dried and crystallised sample plate is loaded into the benchtop MALDI load-lock chamber. Inside the MALDI, a vacuum state is created in as little as two minutes.

qode-eliptic-slider

The Our Process

FIRE LASER

Samples undergo soft ionisation by a laser and the proteins and other biomolecules are separated in the drift tube. The laser is fired 8500 times per each sample, collecting a shot of data, which is then averaged and exported.

qode-eliptic-slider

The Our Process

DATA ANALYSIS

Averaging multiple shots enable us to collect reliable and robust data. The pattern of protein (or other biomolecules) masses are indicative for the condition in question. The intensity of the identified peaks and other extracted features are used in pattern identification.

qode-eliptic-slider

The Our Process

RESULTS

Based on the ever-improving databases, spectral patterns are match and results are obtained through an automated workflow. Our customers can access their results remotely through a safe portal.

Process

Proprietary Applications:

1. Analyse a drop of urine or blood

2. Determine digitally the composition and constituents of the sample by mapping the findings on a digital spectrograph that compares the results to an extensive growing database

3. Provide results instantly from remote network.

Proprietary applications can utilise several different types of samples. Those currently include a microliter of urine, a single pinprick of whole blood, fresh or soaked from a Guthrie card. With minimal pre-processing, we can analyse serum and plasma and non-invasively collected embryo culture fluid.
• The amount required for the analysis is 1µl, which, in most applications is further diluted.
• MAP process enables a very efficient blood sample collection on a Guthrie blood card.
• Novel applications, using a wider sample type are being constantly developed at our Research and Development department.
• This process, from sampling to diagnosis, can take as little as 5-10 minutes.

MALDI ToF process:

The reader does not require any complex pre-processing of samples or multiple chemical or biological agents to convert in series of reactions, instead, it simply analyses the sample, which is held in a single chemical matrix and compares the data to a similar file in the database.

The basic common principle is that a sample is mixed with a single chemical matrix, dried and then soft ionized by a laser and the proteins and other biomolecules are separated in the drift tube and detected. Molecules are separated by the time they take to reach the detector. The intensity of a signal is displayed, and the pattern of protein masses (or other biomolecules) is characteristic of the sample. Databases are constructed of various samples such as different bacteria, yeast, urine, blood, serum, CSF etc. from patients with different conditions. It is then these databases, which are used to compare the unknown samples and find a match.

MAP Approach

New Applications,
New Markets

The Group has developed and patented a direct testing method using an established and approved technology that rapidly diagnose medical disorders. This form of analysis using direct MALDI ToF mass spectrometry is set to revolutionise the in vitro diagnostic arena following a similar approach, which has already seen a transformed microbiology market. This is an entirely new way of analysing samples and not simply a miniaturisation of existing methods. The novelty lies in the power of MALDI ToF to analyse hundreds of variables, very quickly, from a very small volume of biological fluid.

 

The MAP approach is not to measure and quantify individual analytes, but rather take a snapshot of all analytes in a relevant sample to describe and quickly define a clinical picture. It has only been possible to achieve this by looking at medical diagnostics in a completely different way. This is not done over days or weeks using complex protein separation techniques or massive nucleic acid sequencing, but by examining patterns of protein using mass spectrometry in minutes, effectively analysing and interpreting multiple variables in one go. Thus, The Group is not planning to compete in large established markets using a different angle on current methodologies like many diagnostics companies, but rather are developing a completely different approach to medical diagnostics, which has, so far, only been exploited in the field of microbiology. Furthermore, this approach means data can be managed from a distance, securely, and still report results in minutes as if “bedside” or at the point-of-care. The Group will not be entering a market expecting to face competing technology but rather entering existing and emerging markets with entirely new and disruptive technology.